Integrating soluble biomarkers and imaging technologies in the identification of vulnerable atherosclerotic patients
Páramo JA, Rodríguez Ja JA, Orbe J.
Atherosclerosis Research, Division of Cardiovascular Sciences, CIMA, University of Navarra, Pamplona, Spain
The clinical utility of a biomarker depends on its ability to identify high-risk individuals to optimally manage the patient.
A new biomarker would be of clinical value if it is accurate and reliable, provides good sensitivity and specificity, and is available for widespread application. Data are accumulating on the potential clinical utility of integrating imaging technologies and circulating biomarkers for the identification of vulnerable (high-risk) cardiovascular patients. A multi-biomarker strategy consisting of markers of inflammation, hemostasis and thrombosis, proteolysis and oxidative stress, combined with new imaging modalities (optical coherence tomography, virtual histology plus IVUS, PET) can increase our ability to identify such thombosis-prone patients.
In an ideal scenario, cardiovascular biomarkers and imaging combined will provide a better diagnostic tool to identify high-risk individuals and also more efficient methods for effective therapies to reduce such cardiovascular risk. However, additional studies are required in order to show that this approach can contribute to improved diagnostic and therapeutic of atherosclerotic disease.
CITATION Biomark Insights. 2007 Feb 7;1:165-73